在急性冠状动脉综合征中进行抗血栓治疗
Riccardo Rinaldi1, Andrea Ruberti2, Salvatore Brugaletta2
1Hospital Clínic, Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain; Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy.
治疗急性冠状动脉综合征 (ACS) 需要及时进行再注血和抗血栓治疗. 本综述更新了选择抗血栓剂的策略,以平衡凝块预防和出血风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性冠状动脉综合征 (ACS) 管理依赖于机械再输和抗血栓药物.
- 将血栓事件减少与出血风险的平衡对患者的治疗结果至关重要.
研究的目的:
- 提供关于ACS当前抗血栓治疗的全面更新.
- 突出个人化治疗方法在ACS管理中的重要性.
主要方法:
- 对ACS中抗血栓剂的当前文献的综述.
- 分析治疗策略,平衡疗效与安全.
主要成果:
- 多种抗血栓剂可用于ACS治疗.
- 需要仔细选择,以优化利益风险概况.
结论:
- 个性化抗血栓治疗对于有效的ACS管理至关重要.
- 对治疗策略的持续评估是必要的,以改善患者的护理.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...


